For a pharmaceutical company considering a Chinese CMO, CDMO or site-transfer partner, the first useful question is not “Who has a line?” It is “Can the legal entity, product, technical package, quality system and market pathway be brought together in a controlled and documented way?” NMPA Announcement No. 134 (2025) provides a concrete public framework for that question.
What the announcement changes in practical terms
The announcement addresses contract manufacturing of marketed drugs and assigns active responsibilities to both the marketing authorization holder (MAH) and the contract manufacturer. It requires the prospective manufacturer to complete a comprehensive assessment before accepting a project, covering the MAH’s qualifications and quality-management capability, product risk, feasibility of technology transfer and feasibility of co-line production. Only after that evaluation passes may the parties sign the contract-manufacturing agreement and quality agreement.[1]
1. Start with four gates—not a quotation request
| Decision gate | What should be tested | What not to assume |
|---|---|---|
| Legal and regulatory route | Relevant entity, manufacturing scope, licensing pathway, target-market responsibilities and submission assumptions. | A company introduction is not proof that a specific product can be accepted. |
| Product and technical fit | Dosage form, formulation/process maturity, equipment and method compatibility, scale and known development gaps. | A similar dosage form does not prove transfer feasibility. |
| Quality-system fit | Quality agreements, data/record interfaces, change control, deviation escalation, validation and audit access. | An NDA or commercial contract does not define operating quality responsibilities. |
| Co-line and capacity fit | Segregation, cleaning/validation, campaign planning, material controls and co-line risk assessment. | Nominal capacity is not evidence of available or suitable capacity. |
2. Treat technology transfer as evidence creation
The announcement expects the parties to identify, communicate, analyse, assess and handle risks throughout technical transfer; it also expects training, an implemented transfer plan, qualification or validation of relevant facilities, equipment, cleaning, analytical methods and manufacturing processes, and accurate, complete and traceable transfer records.[1] A transfer package therefore needs a named owner, decision criteria and documented acceptance—not merely a folder of legacy documents.
A practical initial dossier should separate: (a) facts already supported by records; (b) facts that require studies or validation; and (c) assumptions awaiting confirmation. This prevents a commercial timeline from being mistaken for a technical conclusion.
3. Apply a higher bar to sterile products
The announcement sets additional conditions for sterile-drug contract manufacturing. In principle, either the MAH or the contract manufacturer should have at least three years of commercial manufacturing experience in sterile drugs of the same dosage form, subject to listed circumstances. For high-risk sterile products, it also calls for MAH personnel to supervise specified validation activities through at least annual on-site inspections, including sterilization-process validation and aseptic-process simulation tests.[1]
These provisions do not create a shortcut for any individual project. They reinforce the need to examine the actual product route, risk profile, people, procedures and evidence at the intended site.
4. Make the quality agreement operational
The announcement requires effective connection between the parties’ quality systems. It expects the quality agreement to give the MAH access to relevant systems, procedures, documents, records and sites involved in the activity, and calls for a quality-information communication procedure covering at least deviations, changes, OOS/OOT results, qualification and validation, stability, pharmacovigilance, regulatory inspection status and adverse credit records.[1]
For a first assessment, convert that requirement into a responsibility matrix: who performs, reviews, approves, communicates, escalates and retains the authoritative record. A contract title alone does not answer these questions.
5. Include stop criteria before work starts
The announcement says the parties should communicate and control risk where technology transfer is difficult because of software/hardware conditions or production and quality-management issues; if the risk is difficult to control effectively, cooperation should be terminated.[1] This is a useful business discipline as well as a regulatory one. Define early which gaps are resolvable work packages and which would prevent a responsible acceptance decision.
Suggested preliminary assessment checklist
- Project identity: legal/working MAH identity, contact owner, product route, dosage form, presentation and target market.
- Regulatory route: current authorization status, expected change pathway, named responsibility for filings and local regulatory questions.
- Technical package: development stage, manufacturing/process history, analytical and stability status, known failures and required studies.
- Site fit: intended line/facility concept, equipment compatibility, special containment/sterility needs, scale and campaign assumptions.
- Quality governance: proposed audit path, QMS interfaces, batch record/data flow, deviation/change/escalation model and quality-agreement owner.
- Transfer plan: named workstream leads, gap list, protocol/report route, acceptance criteria, training and decision dates.
- Co-line risk: product mix, segregation, cleaning validation, material/finished-goods controls and proposed risk assessment.
- Commercial boundary: scope assumptions, information availability, non-binding timeline and conditions precedent to quotation or contracting.
Frequently asked questions
Does the announcement mean every product can be transferred to any Chinese contract manufacturer?
No. It requires a comprehensive project-specific evaluation before acceptance. Legal scope, product risk, technology-transfer feasibility and co-line feasibility all need evidence.
Are sterile products assessed the same way as other dosage forms?
No. The announcement contains additional sterile-product provisions. The actual interpretation and application must be confirmed against the specific project, site and regulatory pathway.
Can a confidentiality agreement replace a quality agreement?
No. They have different functions. Confidentiality protects information; a quality agreement governs quality-related responsibilities and operational interfaces.
Does this article indicate that Hainan Hailing can accept my project?
No. It is an independent, source-based regulatory perspective. Current product-specific technical, quality, capacity, licensing and market assessment remains necessary.
Authoritative sources
This article is a general industry perspective based on public sources. It is not legal, regulatory or medical advice and does not establish any entity’s licensing, availability, project acceptance, product authorization or compliance outcome. Confirm requirements with responsible parties and applicable authorities.